Celgene Corporation (CELG)
-NasdaqGS 124.91 
1.43(1.16%) May 17, 4:00PM EDT|After Hours
:
124.27 0.64 (0.51%) May 17, 4:56PM EDT
| Prev Close: | 123.48 |
|---|
| Open: | 124.84 |
|---|
| Bid: | 120.00 x 300 |
|---|
| Ask: | 125.00 x 100 |
|---|
| 1y Target Est: | 134.22 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | 25-Jul-13 |
|---|
| Day's Range: | 120.35 - 125.05 |
|---|
| 52wk Range: | 58.53 - 131.82 |
|---|
| Volume: | 4,122,228 |
|---|
| Avg Vol (3m): | 3,283,360 |
|---|
| Market Cap: | 52.10B |
|---|
| P/E (ttm): | 38.00 |
|---|
| EPS (ttm): | 3.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Fri, May 17)
- Celgene Corporation (CELG): Today's Featured Health Care Winnerat TheStreet(Fri, May 17)
- Midday Glance: Biotechnology companiesAP(Fri, May 17)
- Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to InvestingWall Street Transcript(Fri, May 17)
- Early Glance: Biotechnology companiesAP(Fri, May 17)
- Today’s 3 Worst Stocksat Motley Fool(Thu, May 16)
- Stocks Close Lower; Dell Little Changed After Earningsat Investor's Business Daily(Thu, May 16)
- [video] Stock Pops & Dropsat CNBC(Thu, May 16)
- Wall Street Turns Down At The Bell; Celgene Sells Offat Investor's Business Daily(Thu, May 16)
- Gilead Drug For Leukemia Shows Success In Early Trialat Investor's Business Daily(Thu, May 16)
- Stocks Flat In Late Trading, But Cisco Lifts Nasdaqat Investor's Business Daily(Thu, May 16)
- 3 Companies That Put the "Tech" in "Biotech"at Motley Fool(Thu, May 16)
- Stocks Little Changed; Qihoo, Ocwen Hit New Highsat Investor's Business Daily(Thu, May 16)
- Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead FundWall Street Transcript(Thu, May 16)
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downwardat TheStreet(Thu, May 16)
Key Statistics
| Forward P/E (1 yr): | 18.10 |
|---|
| P/S (ttm): | 9.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.43 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.96 |
|---|
Business Summary
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries.
View More